Ir-med, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
IRME
Ir-med, INCIR-Med, Inc. reported increased losses and significant cash flow challenges, raising substantial doubt about its ability to continue as a going concern.
OTC.Pink
IRME
Ir-med, INCIR-Med Inc. announces its Q1 2025 financial results, highlighting advancements in its PressureSafe and DiaSafe devices while acknowledging substantial doubt about its ability to continue as a going concern.
OTC.Pink
IRME
Ir-med, INC10-Q: IR-Med Inc. Reports Q3 2024 Results: Operating Losses Narrow as Company Advances Product Development
IR-Med Inc. reported a reduced net loss for the third quarter of 2024 compared to the same period last year, while progressing with the development and commercialization of its medical devices.
OTC.Pink
IRME
Ir-med, INCIR-Med, Inc. reported its Q2 2024 financial results, highlighting a decrease in operating expenses and net loss, while also noting substantial doubt about its ability to continue as a going concern.
OTC.Pink
IRME
Ir-med, INCIR-Med Inc. reported a net loss of $657,000 for the first quarter of 2024 and faces substantial doubt about its ability to continue as a going concern.